Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results From the LATITUDE Study

Targeted Oncology - France
doi 10.1007/s11523-019-00685-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Treatment Sequences, Patient Characteristics, and Overall Survival of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer in the Community Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer

European Urology
Urology
2016English

Predictive Factors of Response and Overall Survival in Patients With Castration-Resistant Metastatic Prostate Cancer Undergoing177Lu-Psma Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2015English

The Addition of Apalutamide to ADT in the Treatment of Metastatic Castration-Sensitive Prostate Cancer: Safety and Efficacy

Expert Review of Anticancer Therapy
OncologyPharmacology
2020English

Medical Resource Utilization of Abiraterone Acetate Plus Prednisone Added to Androgen Deprivation Therapy in Metastatic Castration-Naive Prostate Cancer: Results From LATITUDE

Cancer
Cancer ResearchOncology
2018English

Pcn64 - Review of Nice Hta Submissions Including Methodologies Adjusting for Overall Survival in the Presence of Treatment Switching

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Overall Survival and Second Primary Malignancies in Men With Metastatic Prostate Cancer

PLoS ONE
Multidisciplinary
2020English

Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy

Klinicka Onkologie
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy